2024
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington S, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith S, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson P, Grover N, Merril M, Crombie J, Shafagati N, Sterling C, Nastoupil L, Epperla N, Ayers E. Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers. Haematologica 2024, 0. PMID: 39540227, DOI: 10.3324/haematol.2024.285977.Peer-Reviewed Original ResearchLOTIS-2Overall response rateOverall survivalAntibody drug conjugatesBulky diseaseComplete responseRefractory diffuse large B-cell lymphomaUS centersDiffuse large B-cell lymphomaLarge B-cell lymphomaEvaluate outcomes of patientsHigh riskResponse rateB-cell histologyR/R DLBCL patientsPre-treated patientsB-cell lymphomaOutcomes of patientsProportion of patientsRetrospective cohort studyCell of originDLBCL patientsReal-world settingsRetrospective studyReal-world analysisReal-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e181-e190. PMID: 38433043, DOI: 10.1016/j.clml.2024.01.010.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaHealthcare resource utilizationR-GemOxOverall survivalR/R settingR/R diffuse large B-cell lymphomaElderly patientsLarge B-cell lymphomaDLBCL diagnosisRates of healthcare resource utilizationCombination of rituximabMedian overall survivalR/R DLBCL patientsB-cell lymphomaStem cell transplantationReal-world survivalHealthcare resource useSample of patientsMicro AbstractRelapsed/refractory settingDLBCL patientsThird-lineSecond-lineCell transplantationPost-indexRacial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States
Neparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.Peer-Reviewed Original ResearchAcute myelogenous leukemiaMantle cell lymphomaChronic lymphocytic leukemiaDiffuse large B-cell lymphomaFollicular lymphomaMultiple myelomaWhite patientsBlack patientsCell lymphomaHematologic malignanciesLymphocytic leukemiaTreatment categoriesElectronic health record (EHR)-derived de-identified databaseDiagnosis of acute myelogenous leukemiaLarge B-cell lymphomaTelemedicine uptakeActive patientsLines of therapyB-cell lymphomaMonthly visit ratesMyeloma patientsVisit ratesAnalyzed patientsMyelogenous leukemiaLymphoma
2023
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma. Future Oncology 2023, 20: 317-328. PMID: 38050764, DOI: 10.2217/fon-2023-0191.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaReal-world treatment patternsLarge B-cell lymphomaB-cell lymphomaTreatment patternsMedicare beneficiariesFirst-line treatmentFront-line treatmentHealthcare resource useHealth resource useElderly Medicare beneficiariesUnmet need existsOverall survivalR-CHOPMedicare patientsLater linesOlder adultsTreatmentPatientsLymphomaNeed existsSurvivalTwo-thirdsResource useSame periodP1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTING
Garg M, Puckett J, Kamal‐Bahl S, Raut M, Ryland K, Chakraborty S, Doshi J, Huntington S. P1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTING. HemaSphere 2023, 7: e7912542. PMCID: PMC10429930, DOI: 10.1097/01.hs9.0000973652.79125.42.Peer-Reviewed Original ResearchFunctional status and therapy for older adults with diffuse large B‐cell lymphoma in nursing homes: A population‐based study
Di M, Keeney T, Belanger E, Huntington S, Olszewski A, Panagiotou O. Functional status and therapy for older adults with diffuse large B‐cell lymphoma in nursing homes: A population‐based study. Journal Of The American Geriatrics Society 2023, 71: 2239-2249. PMID: 36882865, PMCID: PMC10483014, DOI: 10.1111/jgs.18302.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaCommunity-dwelling patientsB-cell lymphomaOverall survivalNH patientsCognitive impairmentOdds ratioEnd Results-Medicare databaseAnthracycline-containing regimensDays of diagnosisPopulation-based studyMultivariable logistic regressionPoor overall survivalConfidence intervalsHigh-risk populationAlternative treatment strategiesNursing home careOlder patientsNH residentsFunctional statusPatient preferencesChemoimmunotherapyTreatment strategiesCell lymphoma
2022
Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL)
Garg M, Huntington S, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J. Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2022, 140: 10814-10815. DOI: 10.1182/blood-2022-158026.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaSingle-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood 2022, 139: 413-423. PMID: 34570876, PMCID: PMC8777199, DOI: 10.1182/blood.2021012888.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaDouble-hit lymphomaCNS relapse rateCNS relapseRelapse rateCNS prophylaxisCNS-International Prognostic IndexSystemic high-dose methotrexateAggressive non-Hodgkin lymphomaLarge B-cell lymphomaCNS-IPI scoreHigh-dose methotrexateUS academic centersHigh-risk subgroupsNon-Hodgkin lymphomaRoute of administrationB-cell lymphomaSignificant differencesReal-world outcomesCNS-IPIEvaluable patientsFrontline therapyTesticular involvementAdult patientsProphylaxis strategies
2021
Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database.
Jin Y, Li J, Mun Y, Masaquel A, Hu S, Biondo J, Huntington S. Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database. Journal Of Clinical Oncology 2021, 39: e18514-e18514. DOI: 10.1200/jco.2021.39.15_suppl.e18514.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaOverall survivalBaseline characteristicsTreatment patternsEastern Cooperative Oncology Group scoreHealth outcomesLarge B-cell lymphomaSimilar disease stageRetrospective cohort studyFirst-line therapyBetter overall survivalDays of diagnosisNon-Hodgkin lymphomaRace groupsB-cell lymphomaYears of ageReal-world studyDe-identified databaseSignificant differencesElectronic health recordsAdvanced diseaseR-CHOPCohort studyNext therapyMedicaid insurance
2020
Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients
Di M, Huntington SF, Olszewski AJ. Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients. The Oncologist 2020, 26: 120-132. PMID: 33230948, PMCID: PMC7873335, DOI: 10.1002/onco.13610.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaChimeric antigen receptor T-cell therapyB-cell lymphomaChemotherapy-free approachProphylactic growth factorsOlder patientsStem cell transplantationT-cell therapyClinical trialsGeriatric vulnerabilitiesRefractory settingGeriatric assessmentCell transplantationPalliative careStandard first-line treatmentGrowth factorEarly palliative careFit older patientsTolerance of treatmentUnfavorable biologic featuresUnnecessary dose reductionsFirst-line settingFirst-line treatmentFavorable toxicity profileA Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma
Mato A, Schuster S, Foss F, Isufi I, Kothari S, Ding W, Brander D, Sitlinger A, Rosenthal A, Leis J, Tun H, Kennard K, Nelson A, Falco V, Komari C, Koehler A, Stowe R, He W, Kearney A, Gui M, McKinlay T, Roeker L, Thompson M, Huntington S. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-138896.Peer-Reviewed Original ResearchB-cell lymphomaChronic lymphocytic leukemiaLarge B-cell lymphomaR DLBCLStem cell transplantDuration of responseRichter transformationCombination therapyPrior therapyUnmet medical needTriple combinationPrimary endpointOverall survivalF. Hoffmann-La RocheMedian age 71 yearsMedical needTyrosine kinase inhibitor monotherapyDe novo diffuse large B-cell lymphomaNovo diffuse large B-cell lymphomaIndolent B-cell lymphomaAdvisory CommitteeMajor unmet medical needDiffuse large B-cell lymphomaHoffmann-La RochePhase ICost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCL
2019
Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma
Huntington SF, Zhu W, Hoag JR, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. JNCI Cancer Spectrum 2019, 3: pkz030. PMID: 31360905, PMCID: PMC6649837, DOI: 10.1093/jncics/pkz030.Peer-Reviewed Original ResearchPositron emission tomographyStaging positron emission tomographyDiffuse large B-cell lymphomaLarge B-cell lymphomaLow-value imagingNon-Hodgkin lymphomaLow clinical utilityB-cell lymphomaCohort studyAppropriate imagingGuideline recommendationsConsensus guidelinesCancer careLymphoma subtypesCell lymphomaClinical utilityEmission tomographyRoutine useOlder adultsLymphomaPhysician ownershipPet ownershipTomographyImagingPatients
2018
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma
Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer 2018, 124: 4211-4220. PMID: 30216436, PMCID: PMC6263848, DOI: 10.1002/cncr.31688.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaOlder adultsCell lymphomaPopulation-based cohort analysisHigh-quality cancer careAnthracycline-containing regimenGuideline-adherent therapyHigh-volume providersNumber of patientsLook-back periodCytotoxic regimensSystemic therapyImproved survivalClinical outcomesReduced hospitalizationsLymphoma patientsCancer careCohort analysisMedicare beneficiariesComplex surgeryDLBCL casesLymphomaClinical volumeCosts of relapsed diffuse large B-cell lymphoma among Medicare patients
Huntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leukemia & Lymphoma 2018, 59: 2880-2887. PMID: 29936866, DOI: 10.1080/10428194.2018.1459613.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCost of IllnessFemaleHealth Care CostsHospitalizationHumansInsurance Claim ReviewLymphoma, Large B-Cell, DiffuseMaleMedicareNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeUnited StatesConceptsDiffuse large B-cell lymphomaHealth care costsLarge B-cell lymphomaFirst-line treatmentB-cell lymphomaCare costsHealth care expendituresCare expendituresHigher health care costsOffice visit costsSecond-line therapyFirst-line therapyHigher medical costsLikelihood of relapseRelapsed cohortMedicare patientsMedicare claimsMedical costsVisit costsPropensity scoreOlder adultsPatientsLymphomaTherapyTreatment
2016
Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population
Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population. Blood 2016, 128: 3574. DOI: 10.1182/blood.v128.22.3574.3574.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaFirst-line therapyHealth care utilizationNon-relapse groupRelapsed diffuse large B-cell lymphomaFirst-line treatmentCare utilizationHealth care costsRelapsed cohortSTATinMED ResearchRelapsed groupMedicare beneficiariesCare costsCause health care costsHealth-care utilization analysisSignificant health care savingsHealth care resource utilizationDiffuse large B-cell lymphoma patientsHigher health care utilizationLarge B-cell lymphoma patientsB-cell lymphoma patientsOlder adultsLarge B-cell lymphomaInitial diagnosis dateNon-relapse patients
2015
Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission
Huntington SF, Svoboda J, Doshi JA. Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal Of Clinical Oncology 2015, 33: 1467-1474. PMID: 25823735, DOI: 10.1200/jco.2014.58.5729.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisDecision Support TechniquesFluorodeoxyglucose F18Health Care CostsHumansImmunotherapyLymphoma, Large B-Cell, DiffuseMarkov ChainsMiddle AgedModels, EconomicMultimodal ImagingPositron-Emission TomographyPredictive Value of TestsQuality-Adjusted Life YearsRadiopharmaceuticalsRemission InductionTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsDiffuse large B-cell lymphomaQuality-adjusted life yearsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaComputed tomographySurveillance imagingCost-effectiveness analysisSurveillance strategiesFirst remissionFluorodeoxyglucose positron emission tomography-computed tomographyPositron emission tomography-computed tomographyEmission tomography-computed tomographyPET/CT scansPET/Computed TomographyFirst-line immunochemotherapyRoutine surveillance imagingMinimal survival benefitDecision-analytic Markov modelLittle clinical benefitRoutine computed tomographyImproved clinical outcomesTomography-computed tomographyCost-effectiveness ratioProbabilistic sensitivity analysesUtility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma
Huntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J. Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 2015, 56: 2579-2584. PMID: 25629993, DOI: 10.3109/10428194.2015.1007506.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleFluorodeoxyglucose F18HumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedOutcome Assessment, Health CarePositron-Emission TomographyPrednisoneProportional Hazards ModelsRemission InductionRetrospective StudiesRituximabTomography, X-Ray ComputedVincristineYoung AdultConceptsDiffuse large B-cell lymphomaFluorodeoxyglucose positron emission tomography-computed tomographyPositron emission tomography-computed tomographyEmission tomography-computed tomographyLarge B-cell lymphomaFirst-line therapyMajority of patientsTomography-computed tomographyB-cell lymphomaI-PETPET/CTFrontline therapyClinical utilityInterim PET/CTTreatment PET/CTProgression-free survivalEnd of treatmentLittle clinical utilityPost-treatment assessmentRetrospective studyPretreatment stagingMultivariable modelingPatientsTreatment imagingTherapy
2014
Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma.
Huntington S, Svoboda J, Doshi J. Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma. Journal Of Clinical Oncology 2014, 32: 6526-6526. DOI: 10.1200/jco.2014.32.15_suppl.6526.Peer-Reviewed Original ResearchUtility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL).
Huntington S, Nasta S, Schuster S, Doshi J, Svoboda J. Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL). Journal Of Clinical Oncology 2014, 32: 8549-8549. DOI: 10.1200/jco.2014.32.15_suppl.8549.Peer-Reviewed Original Research